论文部分内容阅读
目的观察急性胰腺炎(AP)治疗过程中生长抑素对胃肠动力的影响。方法从2012年8月至2013年7月共104例AP患者,随机将其分成两组。观察组患者给予生长抑素治疗,对照组患者则给予5-氟尿嘧啶治疗。同时,两组患者均实施胃肠减压和营养支持、禁食及对症支持、抗感染和解痉止痛等常规治疗。治疗5 d后对比两组患者胃肠减压引流量,肠鸣音恢复正常的时间、肛门排便排气、腹胀和呕吐缓解情况,以及两组患者症状缓解情况和治疗效果。结果观察组显效35例,有效15例,总有效率为96.2%(50/52);无效2例,占3.8%(2/52)。对照组显效34例,有效14例,总有效率为92.3%(50/52);无效4例,占7.7%(4/52)。两组患者胃肠减压引流量比较差异无统计学意义(P>0.05),但两组患者在肠鸣音恢复正常的时间、肛门排便排气、腹胀和呕吐缓解情况比较,观察组均明显优于对照组,且差异有统计学意义(P<0.05)。结论在对AP患者进行治疗时,生长抑素对胃肠动力具有一定的改善作用。
Objective To observe the effect of somatostatin on gastrointestinal motility during the treatment of acute pancreatitis (AP). Methods From August 2012 to July 2013 a total of 104 AP patients were randomly divided into two groups. Patients in the observation group were treated with somatostatin and patients in the control group were treated with 5-fluorouracil. At the same time, both groups underwent gastrointestinal decompression and nutritional support, fasting and symptomatic support, anti-infective and antispasmodic analgesics and other conventional treatments. After 5 days of treatment, the gastrointestinal decompression and drainage volume, the time of returning normal bowel sounds, the defecation of anal defecation, the remission of bloating and vomiting were compared between the two groups, as well as the symptom relief and treatment effect of the two groups. Results The observation group was markedly effective in 35 cases, effective in 15 cases, the total effective rate was 96.2% (50/52); invalid in 2 cases, accounting for 3.8% (2/52). In the control group, 34 cases were markedly effective and 14 cases were effective. The total effective rate was 92.3% (50/52), while 4 cases were ineffective, accounting for 7.7% (4/52). There was no significant difference between the two groups in gastrointestinal decompression and drainage (P> 0.05). However, in the two groups, when the bowel sounds returned to normal, anal defecation, abdominal distension and vomiting were relieved, the observation group were significantly Better than the control group, and the difference was statistically significant (P <0.05). Conclusions Somatostatin can improve gastrointestinal motility in the treatment of AP patients.